Nacuity Pharmaceuticals
Nacuity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Fort Worth, Texas, with operations in Carlton South, Victoria, Australia. It develops targeted therapeutics against oxidative stress, the mechanism it holds responsible for a family of blinding eye diseases and chronic conditions. Its lead asset, NPI-001 (N-acetylcysteine amide) tablets, is in development for retinitis pigmentosa and holds U.S. FDA Breakthrough Therapy, Fast Track and Orphan Drug designations; the SLO-RP Phase 1/2 trial reported significantly lower photoreceptor loss than placebo from six months through the 24-month study in retinitis pigmentosa associated with Usher syndrome. A second programme, NPI-002, is an intravitreal implant for the delay of cataract progression and has completed implantation in the final cohort of its Phase 1/2 trial. A third programme addresses cystinosis. The company licensed its founding technology from Johns Hopkins University, is backed by Foundation Fighting Blindness and its venture arm the RD Fund, and partners with Arctic Therapeutics on AT-001 for hereditary cystatin C amyloid angiopathy. Nacuity Pharmaceuticals runs no developer program and publishes no product API, no developer portal and no API documentation; the only machine-readable surface reachable without credentials is the WordPress REST content API behind www.nacuity.com, catalogued here.
Nacuity Pharmaceuticals publishes 9 APIs on the APIs.io network, including Discovery API, Media API, Oembed API, and 6 more. Tagged areas include Company, biopharmaceuticals, pharmaceuticals, ophthalmology, and rare-disease.
The Nacuity Pharmaceuticals catalog on APIs.io includes 1 JSON-LD context.
Nacuity Pharmaceuticals’ developer surface includes product news, support, authentication, and 29 more developer resources.
Kin Score
APIs 9
Individual APIs this provider publishes, each with its own machine-readable definition.
Nacuity Pharmaceuticals Discovery API
Route, type, taxonomy and status discovery documents.
Nacuity Pharmaceuticals Media API
Media library (140 attachments at harvest time).
Nacuity Pharmaceuticals Oembed API
oEmbed 1.0 provider endpoint for nacuity.com URLs.
Nacuity Pharmaceuticals Pages API
Corporate, clinical-programme and press-release pages (29 published at harvest time). Nacuity authors its news items as pages, not as posts.
Nacuity Pharmaceuticals Portfolio API
The `portfolio` custom post type registered by the site theme and used for leadership entries. Registered and reachable, but empty (X-WP-Total 0).
Nacuity Pharmaceuticals Posts API
Blog/news post collection. Registered and reachable, but empty (X-WP-Total 0) — every press release is a page under /news/.
Nacuity Pharmaceuticals Search API
Cross-content search across published objects.
Nacuity Pharmaceuticals Seo API
Yoast SEO head-tag rendering for a nacuity.com URL — the only anonymously readable operation in the yoast/v1 namespace.
Nacuity Pharmaceuticals Taxonomy API
Categories, tags and the `portfolio-types` custom taxonomy. Categories holds one term (Uncategorized, count 0); tags is empty; portfolio-types holds one term (leadership, count 0).
Scroll for all 9
Semantic Vocabularies 1
JSON-LD contexts and semantic vocabularies used across these APIs.
Security Posture 2
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Documentation 1
Reference material describing how the API behaves
Agent Surfaces 3
MCP servers, agent skills, and machine-readable catalogs
Design & Contract 6
Pagination, idempotency, versioning, errors, and events
Access & Security 2
Authentication, authorization, and security posture
Operate 2
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 7
The organization behind the API
Scroll for all 7
Other 10
Properties that don't map to a standard resource type
Scroll for all 10